Related Experiment Video
Updated: Jul 15, 2025
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
12.6K
Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
Wan Miao1, Jinlin Guo1, Huifang Cheng1
1Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, People's Republic of China.
Infection and Drug Resistance
|September 28, 2023
Summary
Advanced age and long treatment duration increase the risk of cefoperazone/sulbactam-induced coagulopathy (CIC). Vitamin K supplementation may protect against CIC. Tigecycline and valproic acid did not increase bleeding risk.
Area of Science:
- Pharmacology
- Clinical Medicine
- Hematology
Background:
- Cefoperazone/sulbactam is an antibiotic combination used for various infections.
- Coagulation disorders have been anecdotally linked to cefoperazone/sulbactam.
- The impact of concurrent tigecycline or valproic acid on cefoperazone/sulbactam-induced coagulopathy (CIC) is unclear.
Purpose of the Study:
- To investigate the risk factors associated with cefoperazone/sulbactam-induced coagulopathy (CIC).
- To determine if tigecycline or valproic acid exacerbates the risk of CIC.
- To identify potential protective factors against CIC.
Main Methods:
- A retrospective, single-center, nested case-control study.
- Propensity score matching (PSM) was employed to balance demographic characteristics.
- Conditional logistic regression and ROC curve analysis were used to identify risk factors and optimal cut-off values.
Main Results:
- Advanced age, extended treatment duration, and higher total cefoperazone/sulbactam dose were independent risk factors for CIC.
- Concomitant vitamin K administration was an independent protective factor against CIC.
- Tigecycline and valproic acid were not found to be associated with an increased risk of CIC.
Conclusions:
- Advanced age and prolonged treatment duration are significant risk factors for cefoperazone/sulbactam-induced coagulopathy.
- Vitamin K supplementation may mitigate the risk of CIC.
- The concurrent use of tigecycline or valproic acid does not appear to increase the risk of CIC.
Related Concept Videos
01:24Disorders of Hemostasis
982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
01:26Factors Affecting the Risk of Infection
11.9K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.9K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
73
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
73
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
129
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
129